|
08:30-10:00 |
|
|
Session 12
Chairpersons: P. Home, H. Toplak
LIPIDS IN THE WRONG PLACE Islet fat
E. Ravussin Intramyocellular
R.A. DeFronzo
Visceral fat/ NASH
G. Perseghin Myocardial/Perivascular/ Epicardical fat
P. Iozzo
|
Session 13
THERAPY IN COMPLEX PATIENTS WITH TYPE 2 DIABETES CURRENT LIMITATIONS & FUTURE TREATMENT OPTIONS Chairpersons: G. Jermendy H. Lebovitz Elderly T2DM Renally impaired T2DM E. Ritz T2DM with vascular complications: Which target? Which treatment? B. Charbonnel Multidrug treatment of T2DM, a challenge for compliance S. Del Prato
|
Session 14
BARIATRIC SURGERY FOR T2DM REVERSAL The evidence
G. Schernthaner The mechanism
E. Ferrannini The risk
A. Keidar The future
F. Rubino |
|
|
|
|
|
|
10:30-12:30 |
|
|
Session 15
Chairperson: J. Skrha
HYPOGLYCEMIA AND CV RISKS Hypoglycemia and CV risks
B. Frier
ACCORD, ADVANCE and VADT
G. Schernthaner
Hypoglycaemia and it's potential contribution to fatal cardiac arrhythmias in T1D and T2D S. Heller |
Session 16
Chairpersons: G.B. Bolli, R. Fagard
INSULIN THERAPY Insulin therapy in type 2 diabetes Not too soon: H. Lebovitz
Not too late: L. Meneghini HbA1c targets should be individualized for all patients with DM
Pro: L. Leiter
Con: P. Home |
Session 17
Chairperson: H. Rosolova
PREVENTION OF CVD Diabetic dyslipidemia statin Vs. combination therapy Pro: R. Bitzur
Con: A. Zambon Risk assessment of universal treatment Assessment: J. Meigs
Treatment: |
|
|
|
|
|
|
13:15-14:00 |
|
|
|
|
|
|
14:00-16:00 |
|
|
Session 19
Chairperson: E. Bonora
SAFETY – OPEN QUESTIONS Incretins
Sulfonylurea
J. Davidson PPAR-agonists
P. Home Insulin
G.B. Bolli
|
Session 20
Chairperson: L. Meneghini NOVEL DRUGS FOR DIABETES Novel mechanisms for the treatment of T2DM
H. Katzeff
The role of bile acid in T2D treatment Y. Handelsman
Anticoagulatation for every diabetic? Pro:
Con: A. Nicolucci
|
Session 21
SMOKING CESSATION - GET READY FOR SUCCESS!
Chairperson: P.M. Nilsson
Evolutionary perspectives on addiction leading to smoking, obesity and drug abuse
P.M. Nilsson Nicotine dependence: Why, how and when?
K.O. Fagerström Th global epidemic smoking cessation strategies. The evidence
R. Fagard Non-pharmacological support and counseling
P. Tønnesen PANEL DISCUSSION |
|
|
|
|
|
|
16:30-18:30 |
|
|
Session 22
Chairperson: M. Shestakova
HYPERGLYCEMIA AND CVD Is hyperglycemia a CV risk factor? Pro: M. Hanefeld
Con: A. Natali
Heart in diabetes A macrovascular disease:
D. Tschoepe
A microvascular disease:
M. Laakso |
Session 23
Chairperson: N.M. Lalic, R.A. deFronzo
PHARMACOLOGICAL APPROACHES TO THE MANAGEMENT OF OBESITY Benefits of control of calorie intake
N. Stern Mechanisms of medications
Comparative efficiency and safety V. Hainer
Sibutramine on CV outcome
A. Scheen |
Session 24
Chairperson: J.P. Després
THE CARDIOMETABOLIC BENEFITS OF MODERATE WEIGHT LOSS Obesity management: Beyond weight loss R. Ross
Reducing visceral adiposity/ ectopic fat: A better therapeutic target than weight loss?
J.P. Després
Variation in body weight associated with hypoglycaemic medication: more than a side effect in type 2 diabetes
Novel hypoglycemic agents inducing weight loss |
|